2.78
0.02 (0.54%)
| Penutupan Terdahulu | 2.76 |
| Buka | 2.80 |
| Jumlah Dagangan | 1,758,094 |
| Purata Dagangan (3B) | 4,433,513 |
| Modal Pasaran | 452,477,088 |
| Harga / Buku (P/B) | 4.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Aug 2026 |
| EPS Cair (TTM) | -2.54 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.69% |
| Nisbah Semasa (MRQ) | 3.96 |
| Aliran Tunai Operasi (OCF TTM) | -95.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.01 M |
| Pulangan Atas Aset (ROA TTM) | -41.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -73.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cabaletta Bio, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.84% |
| % Dimiliki oleh Institusi | 68.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Mar 2026 | 9,677,125 |
| Cormorant Asset Management, Lp | 31 Mar 2026 | 5,500,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |